Table 2 Ocular assessment after hematopoietic stem cell transplantation.

From: A plethora of ocular surface manifestations in a multidisciplinary ocular graft-versus-host disease unit

 

Without cGVHD (n = 22)

With cGVHD (n = 60)

p-value††

Visual acuity

0.80 ± 0.28 (0.90)

0.65 ± 0.28 (0.85)

0.0146

TMH (millimeters)

0.26 ± 0.09 (0.32)

0.27 ± 0.19 (0.84)

0.8620

NITBUT (seconds)

8.36 ± 4.77 (15.63)

3.35 ± 2.91 (9.56)

0.0191

Hyperemia (grade 0–4)

1.04 ± 0.87 (3.00)

1.62 ± 0.93 (3.90)

0.0090

Fluorescein (grade 0–15)

0.54 ± 1.79 (8.00)

3.01 ± 4.15 (15.00)

0.0090

Lissamine (grade 0–9)

0.11 ± 0.47 (2.00)

1.10 ± 1.85 (7.00)

0.0424

Schirmer’s test (millimeters)

11.32 ± 5.15 (15.00)

6.39 ± 5.90 (15.00)

0.0006

Upper lid meiboscore (grade 0–3)

0.88 ± 0.78 (1.00)

1.89 ± 0.89 (2.00)

0.0011

OSDI (grade 0–100)

17.73 ± 26.63 (87.00)

44.91 ± 30.47 (100.00)

0.0005

  1. Data expressed in mean ± standard deviation (median). †Chi-square test; ††Mann–Whitney test; DED: Dry eye disease; cGVHD: Chronic Graft-versus-host disease; TMH: Tear meniscus Height; OD: right eye; OS: left eye; OSDI: Ocular Surface Disease Index.
  2. Significant values are in [bold].
Back to article page